Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Maravai Lifesciences Holdings (MRVI) EBIAT (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of EBIAT data on record, last reported at $37.0 million in Q4 2025.

  • For Q4 2025, EBIAT rose 167.6% year-over-year to $37.0 million; the TTM value through Dec 2025 reached -$130.8 million, up 49.63%, while the annual FY2025 figure was -$130.8 million, 49.63% up from the prior year.
  • EBIAT reached $37.0 million in Q4 2025 per MRVI's latest filing, up from -$75.3 million in the prior quarter.
  • Across five years, EBIAT topped out at $186.9 million in Q2 2021 and bottomed at -$172.5 million in Q3 2024.
  • Average EBIAT over 5 years is $23.3 million, with a median of -$3.9 million recorded in 2023.
  • Peak YoY movement for EBIAT: skyrocketed 12864.56% in 2021, then tumbled 2568.76% in 2024.
  • A 5-year view of EBIAT shows it stood at $127.1 million in 2021, then crashed by 31.22% to $87.4 million in 2022, then tumbled by 203.67% to -$90.6 million in 2023, then surged by 39.65% to -$54.7 million in 2024, then skyrocketed by 167.6% to $37.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $37.0 million in Q4 2025, -$75.3 million in Q3 2025, and -$39.6 million in Q2 2025.